0

CMHC PULSE

Cardio Metabolic Health Congress – Official Blog

Will New AACE Guidelines Help Obesity to be Taken More Seriously?

Updated guidelines strive for obesity to be treated as a chronic condition

The obesity epidemic shows no signs of slowing, with an estimated 640 million people worldwide now considered obese. According to the CDC, every 2 of 3 adults are overweight or obese. Recently, the American Association of Clinical Endocrinologists (AACE), who declared obesity a disease in 2012, released evidence-based management guidelines that recommend obesity be approached as a chronic medical condition. Their rationale for the update? “Obesity medicine lacks comprehensive and evidence-based guidelines that are translatable to real-world clinical care of patients with obesity,” said AACE Obesity Scientific Committee Chair W. Timothy Garvey, MD.
Read more

Insulin Degludec/Liraglutide 1 Step Closer to US FDA Approval

An FDA advisory committee has voted unanimously in favor of approval of the combination type 2 diabetes treatment insulin degludec/liraglutide. The panel also agreed that the combination treatment would at least be appropriate for patients who had previously used an insulin analogue or GLP-1 agonist, but no other consensus was reached regarding which patient types would be suitable candidates. Members of the advisory committee indicated the combination treatment was needed and expressed hope an insulin-containing combination might overcome “insulin inertia” among clinicians.

Medscape Medical News. FDA panel backs Novo Nordisk Insulin-GLP-1 Combination IDegLira. May 25, 2016.